Cyclophosphamide Injection 500 mg – Alkylating Chemotherapy/Immunosuppressant

Cyclophosphamide is a potent alkylating agent (nitrogen mustard derivative) used in oncology and severe autoimmune diseases. The 500 mg injection is supplied as a sterile lyophilized powder (200 mg/mL concentrate when reconstituted). It is a prodrug that requires activation in the liver: cytochrome P450 enzymes convert cyclophosphamide to active metabolites (primarily 4-hydroxycyclophosphamide/aldophosphamide), which then degrade to phosphoramide mustard (the DNA-alkylating moiety) and acrolein. Phosphoramide mustard forms covalent intra- and inter-strand DNA crosslinks (especially at guanine N7) that block DNA replication and transcription, triggering tumor cell apoptosis. Acrolein is a toxic byproduct responsible for the drug’s urotoxicity (hemorrhagic cystitis) 

Uses and Indications

Cyclophosphamide injection is indicated for various malignancies as part of combination chemotherapy regimens. It is active against many hematologic and solid tumors, including Hodgkin and non-Hodgkin lymphomas, multiple myeloma, chronic and acute leukemias, neuroblastoma, breast carcinoma, ovarian adenocarcinoma, retinoblastoma and others. Typical adult dosing (when used alone) is 40–50 mg/kg IV over 2–5 days, or 10–15 mg/kg IV every 1–2 weeks, or 3–5 mg/kg IV twice weekly (total dose varies by protocol). In practice, cyclophosphamide is rarely given as monotherapy; more often it appears in regimens like CHOP (with doxorubicin, vincristine, prednisone), BEP (with bleomycin, etoposide), or as a conditioning agent before bone marrow transplant.

Off-label uses:

Cyclophosphamide’s immunosuppressive effect (lymphocyte depletion) makes it useful in severe autoimmune disorders. Intravenous cyclophosphamide pulses are used in refractory rheumatoid arthritis, systemic lupus erythematosus (especially lupus nephritis), vasculitides (Wegener’s, microscopic polyangiitis), multiple sclerosis, and other steroid-resistant inflammatory diseases. (These indications are NOT on the FDA label and require careful risk–benefit assessment.) In rheumatology, typical pulse dosing might be 500–1000 mg IV monthly.

Formulation:

The 500 mg vial contains cyclophosphamide monohydrate powder. Reconstitute per label: add sterile water for injection to the vial (e.g. 2.5 mL to yield 200 mg/mL). Then further dilute in IV fluid to at most 2 mg/mL (e.g. add to 250–500 mL compatible diluent). Suitable diluents include 5% dextrose or 0.9% saline. The prepared solution is light yellow and should be inspected for particulates; any sign of “melting” or particulate matter requires discarding the vial. Cyclophosphamide is a hazardous drug (cytotoxic). Follow safety protocols when handling – wear gloves, eye protection, and gown; use a chemoprotected syringe/needle, and dispose of sharps properly. Many facilities use a biological safety cabinet for compounding.

Administration and Nursing Technique

• Route and timing: Cyclophosphamide must be given IV only (never IM or subcutaneous), after dilution. There is no intrathecal use – accidental intrathecal administration is fatal. Give by slow infusion: infuse 500 mg (2.5 mL reconstituted to 200 mg/mL) over 15–30 minutes, or longer at high doses, to avoid hypotension and toxicity. (Some protocols call for infusing 1000 mg or more over 2 hours in transplant prep.) It is often given in the morning to allow forced diuresis during waking hours.

• Hydration: Aggressive IV hydration is critical to reduce bladder toxicity. Ensure the patient drinks or receives IV fluids so that urine output remains brisk. In practice, patients are kept on continuous IV fluids (e.g. D5W or saline) during and for 24 hours after infusion. Encourage frequent voiding.

• Adjunctive Mesna (prevent hemorrhagic cystitis): For high-dose regimens (cumulative cyclophosphamide ≥ 60 mg/kg, or single doses >1–2 g/m^2), prophylactic mesna is often used. Mesna binds acrolein in the urine, preventing bladder irritation. The label notes that mesna “has been used to prevent severe bladder toxicity”. Typical mesna dosing is 20–60% of the cyclophosphamide dose, given IV at the same time and again at 4 and 8 hours.

• Preparation and labeling: Reconstituted cyclophosphamide (after adding sterile water) has limited stability. Use immediately or store refrigerated (2–8°C) for up to 8 hours. Once diluted in drip fluids, keep the solution cool and use within 24–36 hours (see Prescriber’s label for exact times). Label the infusion clearly as “Cyclophosphamide – Cytotoxic” and date/time.

• Monitoring during infusion: Check IV access patency (avoid extravasation – cyclophosphamide tissue extravasation requires immediate saline washout). Monitor vital signs; hypotension can occur if infused too rapidly. Observe patient for immediate hypersensitivity (rash, bronchospasm) – though true allergic reactions are rare, histamine release and flushing may occur.

• Post-infusion care: Continue IV fluids post-dose for at least 12–24 hours. Encourage oral fluids and frequent voiding for the next day. Provide antiemetics prophylactically (cyclophosphamide causes moderate-to-severe nausea/vomiting). Common choices are ondansetron or dimenhydrinate given just before and 4–6 hours after the infusion.

Side Effects and Precautions

Cyclophosphamide’s toxicity is largely dose-related. Key adverse effects include:

• Myelosuppression (bone marrow toxicity): Cyclophosphamide can cause profound leukopenia, neutropenia, thrombocytopenia and anemia. This is dose-limiting – nadir blood counts typically occur 7–14 days post-infusion. Severe immunosuppression can lead to life-threatening infections. Monitor CBC with differential before each cycle and weekly during therapy. Do not give cyclophosphamide if marrow reserves are low (e.g. prior radiation, other chemo). Provide growth factor or transfusions if indicated. Instruct the patient to check temperature daily and report fever or signs of infection immediately.

• Hemorrhagic cystitis (urinary toxicity): Acrolein metabolite irritates the bladder lining, causing hemorrhagic cystitis, urethritis, hematuria. This can be severe or even fatal. Preventive measures are essential: ensure adequate hydration and frequent voiding; administer mesna when indicated; check urine for occult blood after treatment. If hematuria occurs, stop cyclophosphamide and evaluate (possible bladder irrigation or cystoscopy).

• Gastrointestinal: Nausea and vomiting are common (often within hours of infusion). Use antiemetics prophylactically. Mucosal ulceration (stomatitis, esophagitis) can occur at high doses.

• Alopecia: Hair loss is frequent and often complete; regrowth occurs weeks after stopping therapy.

• Gonadal toxicity (infertility): Cyclophosphamide is highly gonadotoxic. It can cause ovarian failure and amenorrhea in women and azoospermia in men. The risk is higher with larger cumulative doses and older age. Patients should be warned of possible permanent sterility. Discuss fertility preservation (sperm or oocyte banking) before treatment in appropriate patients.

• Secondary malignancies: Cyclophosphamide is a known carcinogen/genotoxic. Long-term therapy increases risk of new cancers, especially urinary bladder carcinoma and hematologic malignancies (acute leukemia, myelodysplasia). (Urinary tract cancers in cyclophosphamide patients are often linked to hemorrhagic cystitis.) Always emphasize bladder protection and use the minimum effective dose.

• Cardiotoxicity: At very high doses, cyclophosphamide can cause acute cardiac toxicity (myocarditis, pericarditis, heart failure). This is rare at standard regimens, but warrants caution in patients with existing heart disease.

• SIADH/hyponatremia: Rarely, cyclophosphamide can cause severe dilutional hyponatremia (water retention with SIADH-like syndrome). (Ensure patients do not overconsume hypotonic fluids after infusion.)

• Other: Interstitial pneumonitis/pulmonary fibrosis (with extended use), skin pigmentation changes, nail changes. Cyclophosphamide can interfere with wound healing (avoid elective surgeries soon after infusion).

Contraindications and Special Considerations

• Hypersensitivity: Contraindicated if patient has known allergy to cyclophosphamide (rare) (dailymed.nlm.nih.gov).
• Urinary obstruction: Contraindicated in acute bladder outlet obstruction or anuria (dailymed.nlm.nih.gov). Always ensure good renal function and no blockages before giving.
• Pregnancy/Breastfeeding: Cyclophosphamide is teratogenic and abortifacient. Category D – avoid in pregnancy (women of childbearing age must use effective contraception). Use in pregnancy only for life-threatening conditions (e.g. certain cancers, lupus nephritis) and only under specialist care. It is excreted in breast milk, so breastfeeding is contraindicated during treatment.
• Infertility counseling: (as above) Discuss fertility risks with both men and women prior to therapy (dailymed.nlm.nih.gov).
• Vaccinations: Do not give live vaccines during or immediately after therapy. Patients are immunocompromised.
• Drug interactions: There are no major drug-drug interactions via cytochrome P450 inhibition noted (cyclophosphamide requires activation). However, concurrent use with other marrow-suppressants (e.g. radiation, other cytotoxics) synergistically increases neutropenia.

Nursing and Clinical Tips

• Preparation: Before use, check the vial for damage or “melted” contents (cyclophosphamide can crystallize or melt if overheated). Add diluent carefully (the powder may foam). Label the solution once prepared. Use designated cytotoxic equipment and double-glove when handling.

• Hydration: Educate the care team to enforce IV fluids and voiding during and after infusion. (Nurse tip: Record intake/output closely for 24 hours.)

• Antiemetics: Administer anti-nausea meds (ondansetron, dexamethasone) 30–60 min before infusion to improve patient comfort.

• Monitoring: Check vital signs and observe for infusion reactions. Assess urine color and blood periodically. Draw CBC prior to each dose; post-dose, monitor counts weekly until recovery. Check renal function (BUN/Cr) and liver enzymes periodically.

• Patient education: Instruct patients about side effects: hair loss (advise head covering if desired), avoid prolonged sun exposure (photosensitivity). Emphasize reporting any fever, burning on urination, blood in urine, or unexplained bruising immediately. Reinforce strict birth control and postponing pregnancy. Advise them that immune defenses will be low – avoid crowds/sick contacts.

• Handling spills/exposure: As a hazardous agent, any spill must be cleaned up per facility protocol (chemotherapy spill kit). If skin contact occurs, wash thoroughly.

Cyclophosphamide injection is a cornerstone of many treatment protocols due to its broad cytotoxic activity. However, it requires careful dosing, vigorous prevention of bladder toxicity, and close monitoring of blood counts and organ function. By following proper infusion techniques and citing the guidelines above, clinicians can maximize its therapeutic benefits while minimizing risks.

Product Details and Features

Product Name: Cyclophosphamide for Injection
Strength: 500 mg per single-dose vial
Manufacturer: Long Grove
Dosage Form: Sterile powder for reconstitution and intravenous or intramuscular administration
Packaging: Secure and sterile packaging to preserve potency and integrity until reconstitution
Indications: Primarily indicated for the treatment of malignant lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, ovarian carcinoma, and breast carcinoma. Also used in conditioning regimens prior to bone marrow transplantation and in certain autoimmune disorders.
Storage Conditions: Store vials at controlled room temperature, 20°C to 25°C (68°F to 77°F). Protect from light.

Features

• Broad-spectrum Usage: Effective against a variety of cancer types and suitable for autoimmune conditions.
  
• Proven Clinical Efficacy: Well-documented results in oncology as a monotherapy or in combination regimens.
  
• Reliable Manufacturing: Produced by Long Grove, guaranteeing quality assurance in every vial.

Directions for Use

1. Reconstitution: Aseptically reconstitute the 500 mg powder with an appropriate volume of Sterile Water for Injection (as indicated in product literature) to ensure complete dissolution.
2. Administration: Administer intravenously over a specified period or intramuscularly, taking care to consider the therapeutic regimen that may require dose adjustments based on patient tolerance and intended outcomes.
3. Dosage: Dosage is highly individualized according to type and stage of cancer, patient size, and regimen (monotherapy or combination therapy). Medical professionals should establish protocols.
4. Supervision: Therapy should be administered under the superintendency of a qualified medical professional experienced in cancer chemotherapy.

Warnings

• Bone Marrow Suppression: Monitor blood counts frequently as cyclophosphamide can induce leukopenia, thrombocytopenia, and anemia.
  
• Secondary Malignancies: Long-term use may risk developing secondary malignancies.
  
• Toxicity: Risks include cardiotoxicity at high dosages, potential liver toxicity.
  
• Hypersensitivity Reactions: Some patients may demonstrate hypersensitivity leading to adverse reactions.

Side Effects

While cyclophosphamide is often tolerated given its therapeutic importance, it may cause side effects:

• Common: Nausea, vomiting, alopecia, and fatigue.
  
• Serious: Hemorrhagic cystitis due to acrolein (a metabolite); requires adequate hydration and possibly mesna therapy for prevention.
  
• Immunosuppressive Effects: Increased risk of infection due to bone marrow suppression.
  
• Gastrointestinal and Dermatological: Mucosal damage and skin reactions.

Cyclophosphamide for Injection is a critical component in cancer therapy, with proven effectiveness across diverse malignancies. Always consult with healthcare professionals for suitability, dosage, and monitoring to optimize therapeutic outcomes while minimizing adverse effects. Trust Cyclophosphamide by Long Grove to be a cornerstone of effective oncological care.